Your treatment guide to JELMYTO[®] (mitomycin) for pyelocalyceal solution

"Who says cancer treatment has to take my kidney?"


The first and only FDA-approved treatment for low-grade upper tract urothelial cancer (LG-UTUC) in adult patients



Approved Use for JELMYTO

JELMYTO[®] is a prescription medicine used to treat adults with a type of cancer of the lining of the upper urinary tract including the kidney called low-grade Upper Tract Urothelial Cancer (LG-UTUC).

Please <u>click here</u> for JELMYTO Full Prescribing Information, including the Patient Information, for additional information.





Contents

Low-grade UTUC: What you need to know
What is low-grade UTUC?
About JELMYTO
JELMYTO has been proven to treat low-grade tumors
What to expect before treatment
What to expect during treatment
What to expect after treatment
What to expect after treatment
Taking care of yourself during
Taking care of yourself during treatment with JELMYTO
Taking care of yourself during treatment with JELMYTO. Possible side effects with JELMYTO.




3

Low-grade UTUC: What you need to know

As your doctor may have told you, UTUC stands for "upper tract urothelial cancer." It is a rare cancer that develops in the area where urine moves out of your kidney—the good news is that it's treatable.

Urothelial tract



A. Kidney

- Removes waste and extra fluid
- Controls blood pressure
- Makes red blood cells
- Keeps bones healthy

B. Ureter

Moves urine from the kidney to the bladder

C. Bladder

Stores urine

D. Urethra

Moves urine from the bladder to the outside of your body

What is low-grade UTUC?

In UTUC, "low-grade" means your cancer is less aggressive and is slow to spread. Even so, it's still important to treat it.

Treatment helps to control your symptoms and prevent serious kidney damage.

Until now, kidney removal has been one of the standard methods of treating low-grade UTUC, but kidney removal may have a major impact on overall health, including blood pressure and heart disease.

Why it's important to treat your low-grade UTUC

Like all cancers, low-grade UTUC is a serious disease. Without treatment, UTUC can cause significant health problems like permanent kidney damage.

Because your UTUC is low grade, your treatment options include JELMYTO, an alternative treatment to removing your kidney.

Important Safety Information

You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.

Please <u>click here</u> for JELMYTO Full Prescribing Information, including the Patient Information, for additional information.



5



About JELMYTO

JELMYTO is the first and only FDA-approved treatment for low-grade UTUC.

 \bigcirc

JELMYTO is a combination of chemotherapy (mitomycin) and an innovative gel technology that is a **liquid when chilled** and turns into a **gel at body temperature.**



Unlike typical chemotherapy that goes everywhere in your body, your doctor will give you JELMYTO in the affected kidney region where your tumors are. Once there, JELMYTO stays in place for up to 4 to 6 hours to kill cancer cells.

JELMYTO has been proven to treat low-grade tumors

In a study of people who received JELMYTO,

58% of patients treated with JELMYTO had their tumors disappear following their initial course of treatment

Of the patients who responded, the majority were still tumor-free at their 12-month follow-up.

Important Safety Information (cont'd)

The most common side effects of JELMYTO include: urinary tract infection, blood in your urine, side pain, nausea, trouble with urination, kidney problems, vomiting, tiredness, stomach (abdomen) pain.

Please <u>click here</u> for JELMYTO Full Prescribing Information, including the Patient Information, for additional information.



What to expect before treatment

- Your doctor will tell you to take a medicine called sodium bicarbonate before each JELMYTO treatment. Your doctor will provide instructions about how to take this
- Be sure to tell your doctor if you take water pills (diuretic)
- You and your doctor may decide that general anesthesia is right for you, but **general anesthesia is not required** with JELMYTO

Be sure to tell your doctor about your medical conditions and all the medications you take.

Important Safety Information (cont'd)

• **Bone marrow problems.** JELMYTO can affect your bone marrow and can cause a decrease in your white blood cell, red blood cell, and platelet counts. Your healthcare provider will do blood tests prior to each treatment to check your blood cell counts during treatment with JELMYTO. Your healthcare provider may need to temporarily or permanently stop JELMYTO if you develop bone marrow problems during treatment with JELMYTO.

Before receiving JELMYTO, tell your healthcare provider about all your medical conditions, including if you:

• are pregnant or plan to become pregnant. JELMYTO can harm your unborn baby. You should not become pregnant during treatment with JELMYTO. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO.

Females who are able to become pregnant: You should use effective birth control (contraception) during treatment with JELMYTO and for 6 months after the last dose.

What to expect during treatment



Your doctor will give you JELMYTO through a thin flexible tube, called a catheter, once weekly for 6 weeks in an office, hospital, or other outpatient setting.



Because this is an outpatient procedure, you will typically be sent home the same day.

The results seen with JELMYTO were achieved when JELMYTO was given once a week for 6 weeks. Make sure you do not miss any appointments, and reschedule immediately if you do.

Important Safety Information (cont'd)

Males being treated with JELMYTO: If you have a female partner who is able to become pregnant, you should use effective birth control (contraception) during treatment with JELMYTO and for 3 months after the last dose.

- are breastfeeding or plan to breastfeed. It is not known if JELMYTO passes into your breast milk. Do not breastfeed during treatment with JELMYTO and for 1 week after the last dose.
- Tell your healthcare provider if you take water pills (diuretic).

Please <u>click here</u> for JELMYTO Full Prescribing Information, including the Patient Information, for additional information.



What to expect after treatment

JELMYTO may cause your urine to turn a violet to blue color after treatment. Your urine flow should otherwise be normal.

JELMYTO contains chemotherapy that is still active when you urinate after treatment.



Take precautions when you urinate:

- Avoid contact with urine for at least 6 hours after treatment
- Male and female patients both should sit on a toilet, and flush the toilet several times after use
- Wash your hands, inner thighs, and groin with soap and water after urination
- Wash your clothing right away if any urine gets on it, and separately from your other clothing

Taking care of yourself during treatment with JELMYTO

- 🧭 Get lots of rest
- 🔗 Eat healthy foods
- Spend time with friends and family
- 🔗 Quit smoking

It's important to keep all of your appointments. But if you do miss an appointment, call your doctor right away to reschedule.

Important Safety Information (cont'd)

How will I receive JELMYTO?

- Your healthcare provider will tell you to take a medicine called sodium bicarbonate before each JELMYTO treatment.
- You will receive your JELMYTO dose from your healthcare provider 1 time a week for 6 weeks. It is important that you receive all 6 doses of JELMYTO according to your healthcare provider's instructions. If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment. Your healthcare provider may recommend up to an additional 11 monthly doses.
- JELMYTO is given to your kidney through a tube called a catheter.
- During treatment with JELMYTO, your healthcare provider may tell you to take additional medicines or change how you take your current medicines.

Please <u>click here</u> for JELMYTO Full Prescribing Information, including the Patient Information, for additional information.



Possible side effects with JELMYTO

Contact your doctor's office right away if you develop any of the side effects listed below or if they worsen.

Serious side effects may include:

- Swelling and narrowing of the tube that carries urine from the kidney to the bladder (ureteric obstruction): Your doctor may recommend the placement of a small plastic tube (stent) in the ureter to help the kidney drain. This will help you urinate and protect your kidney. Tell your doctor right away if you develop side pain or fever during treatment.
- **Bone marrow problems:** JELMYTO can affect your bone marrow and may cause a decrease in your blood cells. Your doctor will do blood tests before each treatment.

The most common side effects of JELMYTO include:

- urinary tract infection
- kidney problemsvomiting

tiredness

- blood in your urine
- side pain
- nausea
- trouble with urination
- stomach (abdomen) pain

Tell your doctor if you have any side effects that bother you or do not go away.

• You may report side effects to the FDA at 1-800-FDA-1088 or to UroGen Pharma at 1-855-987-6436

What to know if you are sexually active



For women:

- Do not become pregnant during treatment with JELMYTO. If you become pregnant, contact your doctor immediately
- Do not breastfeed during treatment with JELMYTO

For men:

 If you have a female partner who may become pregnant, use effective birth control during treatment with JELMYTO and for 3 months after the last dose

Ask your doctor about effective methods of preventing pregnancy during treatment with JELMYTO.

Important Safety Information (cont'd)

After receiving JELMYTO:

- JELMYTO may cause your urine color to change to a violet to blue color. Avoid contact between your skin and urine for at least 6 hours.
- To urinate, **males and females should sit** on a toilet and flush the toilet several times after you use it. After going to the bathroom, wash your hands, your inner thighs, and genital area well with soap and water.
- Clothing that comes in contact with urine should be washed right away and washed separately from other clothing.

Please <u>click here</u> for JELMYTO Full Prescribing Information, including the Patient Information, for additional information.



Important Safety Information

Approved Use for JELMYTO

JELMYTO[®] is a prescription medicine used to treat adults with a type of cancer of the lining of the upper urinary tract including the kidney called low-grade Upper Tract Urothelial Cancer (LG-UTUC).

Important Safety Information

You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.

Before receiving JELMYTO, tell your healthcare provider about all your medical conditions, including if you:

 are pregnant or plan to become pregnant. JELMYTO can harm your unborn baby. You should not become pregnant during treatment with JELMYTO. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO.

Females who are able to become

pregnant: You should use effective birth control (contraception) during treatment with JELMYTO and for 6 months after the last dose.

Males being treated with JELMYTO: If you have a female partner who is able to become pregnant, you should use effective birth control (contraception) during treatment with JELMYTO and for 3 months after the last dose.

- are breastfeeding or plan to breastfeed. It is not known if JELMYTO passes into your breast milk. Do not breastfeed during treatment with JELMYTO and for 1 week after the last dose.
- Tell your healthcare provider if you take water pills (diuretic).

How will I receive JELMYTO?

- Your healthcare provider will tell you to take a medicine called sodium bicarbonate before each JELMYTO treatment.
- You will receive your JELMYTO dose from your healthcare provider 1 time a week for 6 weeks. It is important that you receive all 6 doses of JELMYTO according to your healthcare provider's instructions. If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment. Your healthcare provider may recommend up to an additional 11 monthly doses.
- JELMYTO is given to your kidney through a tube called a catheter.
- During treatment with JELMYTO, your healthcare provider may tell you to take

additional medicines or change how you take your current medicines.

After receiving JELMYTO:

- JELMYTO may cause your urine color to change to a violet to blue color. Avoid contact between your skin and urine for at least 6 hours.
- To urinate, **males and females should sit** on a toilet and flush the toilet several times after you use it. After going to the bathroom, wash your hands, your inner thighs, and genital area well with soap and water.
- Clothing that comes in contact with urine should be washed right away and washed separately from other clothing.

JELMYTO may cause serious side effects, including:

 Swelling and narrowing of the tube that carries urine from the kidney to the bladder (ureteric obstruction). If you develop swelling and narrowing, and to protect your kidney from damage, your healthcare provider may recommend the placement of a small plastic tube (stent) in the ureter to help the kidney drain. Tell your healthcare provider right away if you develop side pain or fever during treatment with JELMYTO. • Bone marrow problems. JELMYTO can affect your bone marrow and can cause a decrease in your white blood cell, red blood cell, and platelet counts. Your healthcare provider will do blood tests prior to each treatment to check your blood cell counts during treatment with JELMYTO. Your healthcare provider may need to temporarily or permanently stop JELMYTO if you develop bone marrow problems during treatment with JELMYTO.

The most common side effects of JELMYTO include: urinary tract infection, blood in your urine, side pain, nausea, trouble with urination, kidney problems, vomiting, tiredness, stomach (abdomen) pain.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to UroGen Pharma at 1-855-987-6436.

Please <u>click here</u> for JELMYTO Full Prescribing Information, including the Patient Information, for additional information.



15

Important questions to ask your doctor



Understanding your treatment is important. Don't be afraid to ask questions.

Low-grade UTUC is a serious yet treatable disease. Make sure that you're comfortable and have as much information as possible.

What should I expect during my treatment with JELMYTO?

What do I need to know about my treatment schedule?

What happens if I can't make it to the office on the day that my procedure is scheduled?

What are the goals for my treatment?

Will I be able to leave the office right away after treatment with JELMYTO?



Important questions to ask your doctor (cont'd)



How will I know if my treatment is working?

What should I do if I experience a side effect?

Is there a long recovery?

What side effects might be seen with treatment? Is there anything I should look out for?

Will my treatment have an impact on my life or general health?

Additional information and resources

Get more information and learn about support and affordability resources at **JELMYTO.com**.



For the first time, JELMYTO gives patients an FDAapproved treatment for low-grade UTUC

- JELMYTO is given directly where your tumor is, and stays there for up to 4 to 6 hours to kill cancer cells
- Once-weekly dosing for 6 weeks
- Because it's an outpatient procedure, you will typically be able to go home the same day

Please visit JELMYTO.com for more information

Important Safety Information (cont'd)

JELMYTO may cause serious side effects, including:

• Swelling and narrowing of the tube that carries urine from the kidney to the bladder (ureteric obstruction). If you develop swelling and narrowing, and to protect your kidney from damage, your healthcare provider may recommend the placement of a small plastic tube (stent) in the ureter to help the kidney drain. Tell your healthcare provider right away if you develop side pain or fever during treatment with JELMYTO.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to UroGen Pharma at 1-855-987-6436.

Please <u>click here</u> for JELMYTO Full Prescribing Information, including the Patient Information, for additional information.



JELMYTO® and UroGen® are registered trademarks of UroGen Pharma, Ltd. © 2021 UroGen Pharma, Inc. All rights reserved. US-JEL-00219 03/21



